Figure 3.
Figure 3. Hsp90 expressed in ZAP-70+ CLL has increased binding affinity for 17-AAG. (A) Protein lysates from different samples were evaluated for their binding affinity to Hsp90 inhibitors in a competitive binding assay using a biotinylated geldanamycin (biotin-GM) probe and increasing concentrations of 17-AAG. (B) Hsp90 derived from ZAP-70+ CLL cells showed a higher binding affinity for 17-AAG with an IC50 of 31 nM (SEM ± 2), whereas Hsp90 from ZAP-70-CLL cells, and normal B and T cells had an IC50 of 300 nM. Purified recombinant Hsp90 had an IC50 of 600 nM. This experiment was reproduced 3 times.

Hsp90 expressed in ZAP-70+ CLL has increased binding affinity for 17-AAG. (A) Protein lysates from different samples were evaluated for their binding affinity to Hsp90 inhibitors in a competitive binding assay using a biotinylated geldanamycin (biotin-GM) probe and increasing concentrations of 17-AAG. (B) Hsp90 derived from ZAP-70+ CLL cells showed a higher binding affinity for 17-AAG with an IC50 of 31 nM (SEM ± 2), whereas Hsp90 from ZAP-70-CLL cells, and normal B and T cells had an IC50 of 300 nM. Purified recombinant Hsp90 had an IC50 of 600 nM. This experiment was reproduced 3 times.

Close Modal

or Create an Account

Close Modal
Close Modal